Business Context and Reporting Period
Company: Omeros Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: August 9, 2018
Reporting Period: This filing announces financial results for the three and six months ended June 30, 2018. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data. It references a press release (Exhibit 99.1) for the actual figures. Consequently, the filing text does not provide clear values for:
- Revenue
- Profit or Net Loss
- Cash Flow
- Margins
- Debt and Liquidity
Material Changes
The filing text does not disclose specific material changes versus prior periods. It serves only to notify the market that results for the three and six months ended June 30, 2018, have been issued.
Guidance, Outlook, and Risks
The text contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It explicitly states that the information in this report and the accompanying exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 9, 2018) for actual revenue, net loss, and cash position figures.
- Verify the specific clinical trial progress or regulatory updates mentioned in the referenced press release, as this is a biopharmaceutical company.
- Confirm the company's cash runway and burn rate from the detailed financial statements referenced in the exhibit.
- Check for any updates on the company's lead drug candidates (e.g., OMS721, OMS807) which are typically the primary drivers of value for this registrant.